Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

Inclusion Criteria: For group 1 without trastuzumab : * Patients must be ≥ 18 years old * Patients with breast cancer stage I to III * Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab * Patients must have a social security coverage * Patients able to speak, read and understand French For group 2 with trastuzumab : * Patients must be ≥ 18 years old * Patients with breast cancer grade I to III * Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab * Patients must have a social security coverage * Patients able to speak, read and understand French Exclusion Criteria: * History of cancer * Previous chemotherapy * Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular or neuromuscular disease) * Pacemaker implantation * Contraindication to physical condition evaluation * Contraindication to local anesthesia required for microbiopsy * Patients \< 18 years old or patients ≥ 18 years old under guardianship, or supervision * Psychiatric, musculoskeletal or neurologic disorders * Women that are pregnant or breast-feeding